Assessment of the Antifungal Effect of Biotechnological Product-A New Vegan Agent Microbial Chondroitin Sulfate Against Predominant Candida Strains

Basit Öğe Kaydı
dc.contributor.authorErenler, Ayse Sebnem
dc.contributor.authorUnver, Tuba
dc.contributor.authorMelekoglu, Rauf
dc.date.accessioned2026-04-04T13:37:46Z
dc.date.available2026-04-04T13:37:46Z
dc.date.issued2024
dc.departmentİnönü Üniversitesi
dc.description.abstractMicrobial Chondroitin Sulfate (CS), possesses biocompatible, antiallergic, and non-toxic properties due to its polyanionic structure hold potential as an antifungal agent. This study investigated the effectiveness of microbial CS generated from recombinant Escherichia coli C2987 by biotechnological techniques as an antifungal product for treating Candida infections. Chondroitin biosynthesis was conducted utilizing a recombinant non-pathogenic E. coli, generated through the transformation of plasmid pETM6-PACF-vgb, which carries genes (kfoA, kfoC, and kfoF) responsible for chondroitin synthesis, along with the Vitreoscilla hemoglobin gene (vgb). The broth microdilution and agar dilution assays were employed to assess the antifungal activity of microbial CS and commercial CS against predominant Candida strains comparatively. The inhibitory effect of microbial CS against Candida albicans, Candida tropicalis, Candida parapsilosis, , and Candida krusei was greater than that of commercial CS. This study demonstrates the antifungal activity of microbial CS, a pharmacological agent produced from a recombinant source (vegan-halal). Microbial CS can be a potential supportive treatment not only for vaginal candidiasis but also for other Candida infections that may cause skin and mucosal infections, with its supportive effect on connective tissues and its therapeutic-preventive effect on possible Candida infections.
dc.description.sponsorshipResearch Fund of Inonu University [FDK-2020-2354]
dc.description.sponsorshipAcknowledgments This research was supported by the Research Fund of Inonu University (Project no. FDK-2020-2354) .
dc.identifier.endpage2108
dc.identifier.issn1021-9986
dc.identifier.issue5
dc.identifier.orcid0000-0001-7113-6691
dc.identifier.orcid0000-0002-8655-2716
dc.identifier.scopus2-s2.0-85202518231
dc.identifier.scopusqualityQ3
dc.identifier.startpage2100
dc.identifier.urihttps://hdl.handle.net/11616/110051
dc.identifier.volume43
dc.identifier.wosWOS:001330297400001
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherJihad Daneshgahi
dc.relation.ispartofIranian Journal of Chemistry & Chemical Engineering-International English Edition
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250329
dc.subjectAntifungal activity
dc.subjectCandida spp.
dc.subjectMicrobial chondroitin sulfate
dc.subjectVaginal candidiasis
dc.titleAssessment of the Antifungal Effect of Biotechnological Product-A New Vegan Agent Microbial Chondroitin Sulfate Against Predominant Candida Strains
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu